CD274 and neoplasm: Other than PD-L1 expression, and other potential predictors of immune check-point inhibitor effectivity, it is particularly worthy to discuss microsatellite instability (MSI)/mismatch repair status (MMR), Epstein–Barr virus (EBV) status, and tumour mutation burden (TMB) [59,60].